Tissue Plasminogen Activator for Acute Ischemic Stroke¶
Why this mattered¶
Before this trial, acute ischemic stroke was largely managed as a condition to diagnose, support, and rehabilitate rather than one to reverse in real time. Earlier thrombolysis studies had been shadowed by intracerebral hemorrhage, making clot-dissolving therapy seem too dangerous for routine stroke care. The NINDS rt-PA trial changed that frame by showing that carefully selected patients treated with intravenous recombinant tissue plasminogen activator within three hours of symptom onset were more likely to have minimal or no disability at three months, despite an increased risk of symptomatic intracerebral hemorrhage. Its central shift was not simply that a drug worked, but that acute ischemic stroke became a time-critical, treatable emergency.
The paper made several things newly possible. It established a practical therapeutic window, tied benefit to rapid recognition and treatment, and gave hospitals a reason to build organized stroke pathways: emergency triage, urgent neuroimaging to exclude hemorrhage, protocolized eligibility assessment, and specialist stroke teams. The phrase “time is brain” became operational rather than rhetorical. Stroke care began to resemble myocardial infarction care in one crucial respect: minutes could determine salvageable tissue, disability, and long-term outcome.
Its influence also set the stage for later breakthroughs. Intravenous alteplase became the first widely adopted reperfusion therapy for acute ischemic stroke and created the clinical infrastructure needed for advanced imaging selection, expanded treatment-window studies, comprehensive stroke centers, and ultimately endovascular thrombectomy for large-vessel occlusion. Later trials refined who benefits, how late treatment can be offered, and when mechanical clot retrieval outperforms medication alone, but they built on the conceptual foundation this study made credible: ischemic stroke is not only a vascular catastrophe to classify after the fact, but an emergency in which rapid reperfusion can change the patient’s future.
Abstract¶
Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within three hours of the onset of stroke.
Related¶
- enables → Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke — The tPA trial established rapid reperfusion as an effective acute-stroke treatment principle that endovascular thrombectomy trials extended to mechanical clot removal.
- cite ← Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke — ESCAPE cites the NINDS tPA trial as the established intravenous thrombolysis baseline for acute ischemic stroke treatment.